Fulvestrant has proven clinical benefit in HR-positive and HER2 negative breast cancer, predominantly in postmenopausal women.

Fulvestrant has been employed in patients with 'advanced' disease, including tumors of a very large size or those that metastasize heavily into the lymph nodes. It also includes tumors that have invaded the surrounding tissues and organs.